Open Access

Identification and in silico characterization of p.G380R substitution in FGFR3, associated with achondroplasia in a non-consanguineous Pakistani family

  • Muhammad Ajmal1,
  • Asif Mir2,
  • Muhammad Shoaib3,
  • Salman Akbar Malik4 and
  • Muhammad Nasir1Email author
Diagnostic Pathology201712:47

https://doi.org/10.1186/s13000-017-0642-3

Received: 13 May 2017

Accepted: 29 June 2017

Published: 5 July 2017

Abstract

Background

The dimerization efficiency of FGFR3 transmembrane domain plays a critical role in the formation of a normal skeleton through the negative regulation of bone development. Recently, gain-of-function mutations in the transmembrane domain of FGFR3 has been described associated with an aberrant negative regulation, leading to the development of achondroplasia-group disorders, including achondroplasia (ACH), hypochondroplasia (HCH) and thanatophoric dysplasia (TD). Here, we describe a non-consanguineous Pakistani family with achondroplasia to explain hereditary basis of the disease.

Methods

PCR-based linkage analysis using microsatellite markers was employed to localize the disease gene. Gene specific intronic primers were used to amplify the genomic DNA from all affected as well as phenotypically healthy individuals. Amplified PCR products were then subjected to Sanger sequencing and RFLP analysis to identify a potentially pathogenic mutation. The impact of identified mutation on FGFR3 protein’s structure and stability was highlighted through different bioinformatics tools.

Results

Genetic screening of the family revealed a previously reported heterozygous c.1138 G > A (p.G380R) mutation in the coding exon 8 of FGFR3 gene. Identified genetic variation was confirmed in all affected individuals while healthy individuals and controls were found genotypically normal. The results were further validated by RFLP analysis as c.1138 G > A substitution generates a unique recognition site for SfcI endonuclease. Following SfcI digestion, the electrophoretic pattern of three bands/DNA fragments for each patient is indicative of heterozygous status of the disease allele. In silico studies of the mutant FGFR3 protein predicted to adversely affect the stability of FGFR3 protein.

Conclusions

Mutation in the transmembrane domain may adversely affect the dimerization efficiency and overall stability of the FGFR3, leading to a constitutively active protein. As a result, an uncontrolled intracellular signaling or negative bone growth regulation leads to achondroplasia. Our findings support the fact that p.G380R is a common mutation among diverse population of the world and like other countries, can be used as a molecular diagnosis marker for achondroplasia in Pakistan.

Keywords

Achondroplasia FGFR3 Transmembrane domain Mutation Pakistan

Background

Achondroplasia (ACH) is inherited as an autosomal dominant trait of skeletal dysplasia with an estimated incidence ranging from 1:10,000 to 1: 70,000 live births [1, 2]. It is known to be the most common cause of dwarfism characterized by short stature that particularly affects the appendicular skeleton (upper and lower limbs) and to less extent, axial skeleton (skull, vertebrae, ribs) of the body [35].

Clinically, ACH patients represent typical features including shortened arms and legs (especially the upper arm and thigh), bowed lower legs, disproportionately large head-to-body size, frontal bossing and midface retrusion or hypoplasia [57]. During infancy, hypotonia is the most prominent characteristic caused by delayed and abnormal development of motor milestone [8]. Despite all these clinical manifestations, individuals with ACH have normal life span and intelligence factor [9].

Over the last two decades, dominant gain-of-function mutations of the specific site in fibroblast growth factor receptor 3 (FGFR3) have been shown implicated in human skeletal dysplasias, including achondroplasia (ACH), hypochondroplasia (HCH), thanatophoric dysplasia (TD) and severe achondroplasia, with developmental delay and acanthosis nigricans (SADDAN) [4, 10]. The FGFR3 is one of the four members of fibroblast growth factor receptor (FGFR) family, but differs from other FGFRs in its affinity for ligands and tissue distribution as it is mainly expressed in cartilage and brain [11, 12].

A typical FGFR contains an extracellular ligand-binding domain, a transmembrane region and an intracellular divided tyrosine kinase domain. Fibroblast growth factor (FGF) binds to an extracellular ligand-binding domain to initiate FGF/FGFR signaling that induces the expression of cell cycle suppression genes to negatively regulate bone development. However, mutations in the FGFR3 gene lead to a constitutively active FGFR3 protein. As a result, a cascade of uncontrollable signal transduction allows an aberrant expression of the suppression genes, hence development of short stature pathology [10].

Almost 98% of the ACH cases are caused by variation at nucleotide position 1138, with 97% involving a c.1138 G > A mutation and 1% involving a c.1138 G > C mutation [13, 14]. Both mutations substitute glycine with arginine (p.G380R) in the transmembrane domain of FGFR3 protein that leads to gain-of-function [4, 15]. Mostly these mutations are de novo (sporadic) as more than 80% of ACH cases are born to their average-statured parents [16]. Advanced paternal age is one of the major reasons that significantly contribute to de-novo mutations in the germ cells because of large number of cell divisions during spermatogenesis [17]. Moreover, the presence of guanine at nucleotide position 1138, which is a part of CpG dinucleotide island and the most mutable site in the human genome, can also explain the high incidence of spontaneous mutations in FGFR3 [18]. Other less frequent mutations are also identified in FGFR3 but are mainly associated with hypochondroplasia and thanatophoric dysplasia type I and II [19]. Therefore, in comparison to other genetic diseases, ACH is a genetically and phenotypically homogenous disorder where very few rather than hundreds of mutations are responsible [20, 21]. In this study a non-consanguineous Pakistani family involving two affected generations, was clinically and genetically characterized for skeletal dysplasia. Genetic analysis revealed a heterozygous dominant mutation in FGFR3 affecting the protein stability and dimerization efficiency, leading to ACH in a Pakistani family.

Methods

Subjects

A non-consanguineous Pakistan family with a history of ACH in two consecutive generations was identified from secluded area of KPK, Pakistan. Affected (n = 3) as well as phenotypically healthy individuals (n = 3) were clinically evaluated and blood samples were collected from individuals who consented to the study. Blood samples from hundred ethnically-matched unrelated healthy individuals were also collected to be used as a control for allele frequency calculation and validation of disease-associated mutation. Genomic DNA from peripheral blood samples was extracted by standard phenol–chloroform DNA extraction procedure [22].

Genotyping

Genomic DNA from six family members was genotyped by using FGFR3 linked microsatellite markers; D4S412, D4S2366, D4S394, D4S403, D4S419, D4S391, D4S405, and D4S1627. Standard PCR protocol was followed to amplify microsatellite markers using genomic DNA. Each reaction was carried out in 10 μl volume containing 1.5 mM MgCl2, 0.6 μM of each primer, 0.2 mM each dNTPs, 1 U Taq DNA polymerase and 1× PCR buffer (Bio-line, London, UK). Thermocycler conditions included an initial denaturation at 94 °C for 5 min, followed by 35 cycles of denaturation at 94 °C for 45 s, annealing at 55 °C for 45 s, extension at 72 °C for 45 s and a final extension at 72 °C for 10 min. The PCR products were separated on an 8% non-denaturing polyacrylamide gel stained with ethidium bromide and alleles were assigned through visual inspection.

Sanger sequencing and RFLP

Intronic primers (see Additional file 1) were used to amplify all coding exons and adjacent splice sites to identify any potential pathogenic variant of FGFR3. Amplified PCR products were purified through QIAquick PCR Purification Kit (Qiagen, U.K.) and subjected to bidirectional Sanger sequencing using Big Dye® Terminator v3.1 cycle sequencing kit in an ABI 3130 genetic analyzer (Applied Biosystems, Foster City, CA, U.S.A).

For RFLP analysis, the candidate region of FGFR3 was PCR amplified using genomic DNA of all available samples. Amplified products were purified and digested with site specific restriction enzyme at 37 °C for 16 h by following manufacturer’s instructions (Thermo Scientific). The digested products were separated on 3% agarose gel and genotypes were called by visual inspection under UV. To ensure the mutation does not exist in our population as a common polymorphism, hundred ethnically-matched controls were also screened.

In silico analysis

Secondary and tertiary structure features of the wild-type/mutant proteins were predicted by Psipred [23] and I-Tasser [24, 25] respectively. RAMPAGE server [26] confirmed the accuracy of models. Pockets on three-dimensional structures of proteins were identified using CASTp server [27, 28]. Meta SNP [29], I-Mutant2.0 [30] and PredictSNP [31] were utilized to estimate the effect of mutation on protein stability and to determine whether the identified mutation has an impact on normal function of protein or not.

Sequence acquisition

Reference sequences of FGFR3 gene (NG_012632.1), coding nucleotides (NM_000142.4) and amino acids (NP_000133.1) were retrieved through NCBI database.

Results

Clinical details

Abnormal endochondral ossification of long bones was a primary prominent defect observed in all patients. This resulted in shorter and broader tubular bones, particularly the femur (thigh bone) and humerus (arm bone), compared to an average aspect ratio (length/width) of bone in a normal population (Fig. 1a-f). The growth pattern of iliac crest remained normal; however, the standing heights were dropped below the third percentile of the age.
Fig. 1

Clinical presentation of a Pakistani family with autosomal dominant achondroplasia: (a) Affected individuals showing short stature with near to normal head growth. Shortened hands of father (II-3) are prominent but not evident in children due to their younger ages. b, c Represent affected individuals III-1 and III-2 in the pedigree respectively; facial and skull growth pattern is near to normal with mild flat nasal bridge. Axial skeleton is less affected, whereas shortened humerus is prominent. d, e Affected individuals III-1 and III-2 in the pedigree respectively; both children are displaying bilateral bowing of legs and little feet intoeing. f Affected individual II-3 in the pedigree; an adult presenting characteristic bilateral bowing of tibia

Facial and skull growth pattern was near to normal in affected individuals. The morphology of hands was smaller than the average growth in adults only because in children it cannot be marked (Fig. 1a). The axial skeleton was relatively involved but the appendicular skeleton was more prominent to be rhizomelic (Fig. 1b and c).There was bilateral tibial bowing in all patients; however, a little element of intoeing secondary to the bowing of legs in children was clinically and physically obvious (Fig. 1d-f). The gait cycle of walk was also normal. The cognitive system of all our patients was spared. The intelligence was also within normal values; however, there was a history of gross motor developmental delay meant that children had delayed milestones during their initial development. Remaining neurological examinations were normal. The soft tissue structures of gastrointestinal system, genitourinary system, respiratory system and visual and acoustic systems all were in the normal range.

Genotyping and mutation analysis

Genotyping of each three affected and normal individuals (Fig. 2a) by using microsatellite markers mapped the disease at cytogenetic locus 4p16.3. The markers were fully informative and their heterozygous status in all affected individuals suggesting the disease linkage to the locus carrying previously reported FGFR3 gene.
Fig. 2

The ACH family pedigree and DNA sequence analysis: (a) Pedigree of a non-consanguineous Pakistani family where ACH is segregating as dominant trait. Three affected individuals (II-3, III-1, III-2) and three phenotypically healthy individuals (II-1, II-2, II-4) were analysed. b Sanger sequencing of FGFR3 gene revealed a c.1138 G > A heterozygous mutation in affected individuals while homozygous wild-type allele (G/G) in phenotypically healthy individuals. Arrow indicates the site of mutation. c PCR-RFLP analysis; an electrophoretic banding pattern of SfcI digestion revealed homozygous status for all healthy individuals while heterozygous condition observed in affected individuals

Sanger sequencing detected a heterozygous G > A substitution at nucleotide position 1138 (c.1138 G > A) in coding exon 8 of the FGFR3 causing glycine replacement with arginine (p.G380R). Affected individuals were found heterozygous for the change while phenotypically healthy individuals identified with normal genotype (Fig. 2b). Identified variation was not found in a panel of hundred ethnically-matched control samples. Sequences were compared with the NCBI reference sequence; NG_012632.1.

RFLP results were analyzed by simply counting and comparing the bands sizes in healthy as well as affected individuals. Digestion with SfcI restriction enzyme produced expected banding pattern; a single band of 545 bp was observed in healthy individuals while three fragments of sizes 545 bp, 313 bp and 232 bp were identified in affected s individuals. The banding pattern observed in all affected individuals not only indicates the heterozygous status of the disease allele but also confirms the presence of SfcI restriction site created by c.1138 G > A mutation (Fig. 2c).

In silico analysis of secondary structure features and protein stability

Protein secondary structure analysis showed number of features such as alpha helices, beta sheets and coils in both forms of the protein (Fig. 3a). This shows a little variation in the number of structure features but still has a significant impact on overall conformation of the structure, hence its interaction and function. This can further be seen in three-dimensional structure modeling where normal structure has been shown in part B while mutation is highlighted in part C. Structure evaluation also indicated reliability of the predicted models by showing maximum number of residues in favored region.
Fig. 3

Structure modeling: (a) PsiPred results showing number of secondary structure features in the wild-type and mutant forms of FGFR3. b Three-dimensional structure prediction of wild-type FGFR3 using I-Tasser. Red cylinders showing α-helix, flattened cyan color arrows showing β-Sheets and rest tube like features are coils. c Superimposed three-dimensional structures of wild-type and mutant highlighting the substituted amino acid. Superimposed structures represented by purple wire display style while red ball & stick model is representing arginine which got substituted by glycine (green color stick display style) at 380 amino acid position (p.G380R)

As per I-Mutant2.0 calculations, protein stability decreases due to amino acid substitution. For this, two additional tools i.e. PredictSNP & Meta SNP were also utilized to analyze the effect of mutation on protein (Fig. 4a and b). PredictSNP utilizes data from different powerful predicting methods, integrates and computes the data to produce more accurate and significantly improved predictions on functional status of a protein. PredictSNP sorts out SNPs with damaging consequences as natural variant of disease phenotype. Generally, in such conditions, stability of protein is compromised. Contrary to this, SNPs are mostly classified as neutral/ benign those with no known disease symptoms. Meta SNP also hires with it different predictors (PATHER, PhD-SNP, SIFT and SNAP) to calculate mutation impact on normal protein. The values reported for each prediction are summarized in Fig. 4b. Maximum number of predictors anticipated p.G380R mutation as a disease causing which further validated our results. Reference values for prediction tools are given in Additional file 2.
Fig. 4

FGFR3 Mutation (p.G380R) effect prediction: (a) PredictSNP results. b Meta SNP results

Discussion

Achondroplasia, primarily a failure of endochondral ossification in the growth plate of cartilage, defined to be associated with pathogenic mutations in the transmembrane segment of FGFR3 gene [32, 33]. To date, eight different pathogenic mutations of FGFR3 transmembrane segment have been shown implicated in cancer and growth disorders including ACH; however, exact pathogenetic mechanism of the disease is still unclear. In the present study, we screened a non-consanguineous Pakistani family with ACH and identified a highly recurrent heterozygous c.1138 G > A mutation of FGFR3. The single nucleotide substitution not only replaces glycine with arginine at codon position 380 (p.G380R) but also generates a unique restriction site for SfcI endonuclease. An electrophoretic banding pattern of SfcI digestion supports the dominant mode of disease segregation in the family. The presence of heterozygous c.1138 G > A mutation in all affected individuals, but none of the phenotypically normal members of the family along with hundred ethnically-matched healthy controls confirms the previously reported association of mutation with ACH in this Pakistani family.

The identified genetic variation was further tested through in silico analysis to calculate its impact on protein structure, stability and function attributed to disease under study. Comparative in silico analysis of varied features of wild-type and mutant FGFR3 proteins predicted significant conformation changes in the secondary protein structure. As a consequence, decreased protein stability with altered interaction and function can be expected. The Identified mutation has previously been described to be implicated in persistent ligand-independent activation of the FGFR3 protein, a deviation from its normal function as a negative bone growth regulator [4, 18]. In the present study, it was calculated through bioinformatics that the identified mutation decreases the protein stability, hence disrupted the normal functioning of FGFR3 protein completely or partially and categorized as deleterious ACH mutation.

Under normal circumstances, FGF/FGFR3 signaling initiates lateral dimerization of FGFR3 monomers to take on autophosphorylation of tyrosine residues in the intracellular domain of FGFR3 [34]. The transmembrane domain plays a critical role in this dimerization and/or activation of receptor tyrosine kinases by controlling orientation of the intracellular kinase domain [35, 36]. Once activated, FGFR3 phosphorylate cytoplasmic target proteins, leading to the activation of intracellular downstream signaling cascade. Signaling Pathways such as mitogen-activated protein kinase (Ras/MAPK), phosphoinositide 3-kinase/Akt, phospholipase C and protein kinase C pathways inhibit chondrocyte proliferation through STAT1 signaling by inducing the expression of cell cycle suppressor genes such as CDK inhibitor p21, hence negatively regulate bone growth [10, 37].

In contrast, both the deficiency of FGFR3 or presence of gain-of-function mutations in FGFR3 are reportedly implicated in prolonged bone growth or short stature respectively, suggesting the role of FGFR3 as limiting factor rather than a promoting agent [10, 38, 39]. Among the known mutations of FGFR3, c.1138 G > A substitution (p.G380R) is the most recurrent point mutation ever known in human genome accounts for almost 98% ACH cases [18, 4042]. It is considered that p.G380R change causes hydrogen bonding between two arginine side chains that stabilizes FGFR3 dimerization in the cell membrane, leading to a constitutive ligand-independent activation of the FGFR3 [43]. Thus, uncontrollable signal transduction promotes the inhibition of cartilage growth and development by aberrantly inducing the expression of cell cycle suppressor genes [35, 43]. Many other studies have hypothesized that point mutations in the FGFR3 transmembrane regions can induce conformational rearrangements of the dimer that can affect its association strength in different states and hence represent a general mechanism of activation of such receptors [40, 43]. However, the exact mechanism of FGFR3-mediated signal transduction in health and disease is still unknown.

Conclusion

We report a common FGFR3 substitution mutation p.G380R in three patients from a non-consanguineous Pakistani family. In view of previous reports we assume that the identified mutation might have altered the dimerization efficiency of transmembrane region leading to uncontrolled signal transduction and expression of cell cycle suppressor genes. This might clarify the decreased cell proliferation in the growth plate and would justify the basis for reduced endochondral bone growth and disproportionate short stature in ACH. Further detailed genotype-phenotype studies are expected to provide a better understanding of the role of FGFR3 in skeletal development. Our findings agree with the world-wide sharing of p.G380R mutation among achondroplasia subjects and extend the body of evidence that supports the role of FGFR3 gene in ACH. Moreover, like many other countries, Sfc1 restriction site in FGFR3 can be used as a molecular diagnosis marker for ACH in Pakistan.

Abbreviations

ACH: 

Achondroplasia

CDK: 

Cyclin-dependent kinase

FGFR3: 

Fibroblast growth factor receptor 3

HCH: 

Hypochondroplasia

KPK: 

Khyber Pakhtunkhwa

MAPK: 

Mitogen-activated protein kinase

RFLP: 

Restriction fragment length polymorphism

SADDAN: 

Severe achondroplasia, with developmental delay and acanthosis nigricans

STAT1: 

Signal transducer and activator of transcription 1

TD: 

Thanatophoric dysplasia

Declarations

Acknowledgements

We would like to thank the patients and their family members who contributed in this study. We are also grateful to Mr. Tahir Malik, Team Leader in Biomedical Engineering Department, Hillingdon Hospital, Pield Heath Rd., Uxbridge Middlesex, UB8 3NN, UK, for proof-reading the manuscript and providing valuable suggestions.

Funding

Not applicable. No funding was received.

Availability of data and materials

All data generated or analysed during this study are included in this published article and its additional information files.

Authors’ contributions

MA designed the study, performed experimental work and paper writing, AM provided protein modelling expertise and report writing, MS provided clinical expertise and report writing SAM participated in paper drafting and assisted in study design, MN participated in data analysis, paper editing, formatting and finalization. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The Advance Studies and Research Board (AS&RB), Quaid-i-Azam University, Islamabad, Pakistan (Ref. No. QAU/AS&RB/S-19/Meeting-305/16) and the Ethical Committee of Institute of Biomedical and Genetic Engineering Islamabad, Pakistan (Ref. No. IBGE/IEC/18/01/16) both have reviewed and approved the study. The study conforms to the principles of the declaration of Helsinki. Informed written consent from participants, in the case of children from their parents, was obtained on institutional consent form.

Consent for publication

Written informed consent for publication of their clinical details and/or clinical images was obtained from the patient/parents of the patients who were minors. Copies of the consent forms are available for review by the Editor of this journal.

Competing interests

The author(s) declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Institute of Biomedical and Genetic Engineering
(2)
Department of Biotechnology, International Islamic University
(3)
KRL General Hospital, Orthopedic Department
(4)
Department of Biochemistry, Quaid-i-Azam University

References

  1. Trujillo-Tiebas MJ, Fenollar-Cortes M, Lorda-Sanchez I, Diaz-Recasens J, Carrillo Redondo A, Ramos-Corrales C, Ayuso C. Prenatal diagnosis of skeletal dysplasia due to FGFR3 gene mutations: a 9-year experience : prenatal diagnosis in FGFR3 gene. J Assist Reprod Genet. 2009;26:455–60.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Henderson S, Sillence D, Loughlin J, Bennetts B, Sykes B. Germline and somatic mosaicism in achondroplasia. J Med Genet. 2000;37:956–8.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Savarirayan R, Rimoin DL. The skeletal dysplasias. Best Pract Res Clin Endocrinol Metab. 2002;16:547–60.View ArticlePubMedGoogle Scholar
  4. Shiang R, Thompson LM, Zhu YZ, Church DM, Fielder TJ, Bocian M, Winokur ST, Wasmuth JJ. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell. 1994;78:335–42.View ArticlePubMedGoogle Scholar
  5. Panda A, Gamanagatti S, Jana M, Gupta AK. Skeletal dysplasias: a radiographic approach and review of common non-lethal skeletal dysplasias. World J Radiol. 2014;6:808–25.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Ho NC, Guarnieri M, Brant LJ, Park SS, Sun B, North M, Francomano CA, Carson BS. Living with achondroplasia: quality of life evaluation following cervico-medullary decompression. Am J Med Genet A. 2004;131:163–7.View ArticlePubMedGoogle Scholar
  7. Naidu S, Murphy M, Moser HW, Rett A. Rett syndrome--natural history in 70 cases. Am J Med Genet Suppl. 1986;1:61–72.View ArticlePubMedGoogle Scholar
  8. Carter EM, Davis JG, Raggio CL. Advances in understanding etiology of achondroplasia and review of management. Curr Opin Pediatr. 2007;19:32–7.View ArticlePubMedGoogle Scholar
  9. Kale L, Khambete N, Sodhi S, Kumar R. Achondroplasia with oligodontia: report of a rare case. J Oral Maxillofac Pathol. 2013;17:451–4.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Su N, Jin M, Chen L. Role of FGF/FGFR signaling in skeletal development and homeostasis: learning from mouse models. Bone Res. 2014;2:14003.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Kelleher FC, O'Sullivan H, Smyth E, McDermott R, Viterbo A. Fibroblast growth factor receptors, developmental corruption and malignant disease. Carcinogenesis. 2013;34:2198–205.View ArticlePubMedGoogle Scholar
  12. Su N, Xu X, Li C, He Q, Zhao L, Li C, Chen S, Luo F, Yi L, Du X, et al. Generation of Fgfr3 conditional knockout mice. Int J Biol Sci. 2010;6:327–32.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Hung CC, Lee CN, Chang CH, Jong YJ, Chen CP, Hsieh WS, Su YN, Lin WL. Genotyping of the G1138A mutation of the FGFR3 gene in patients with achondroplasia using high-resolution melting analysis. Clin Biochem. 2008;41:162–6.View ArticlePubMedGoogle Scholar
  14. He X, Xie F, Ren ZR. Rapid detection of G1138A and G1138C mutations of the FGFR3 gene in patients with achondroplasia using high-resolution melting analysis. Genet Test Mol Biomarkers. 2012;16:297–301.View ArticlePubMedGoogle Scholar
  15. Rousseau F, Bonaventure J, Legeai-Mallet L, Pelet A, Rozet JM, Maroteaux P, Le Merrer M, Munnich A. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature. 1994;371:252–4.View ArticlePubMedGoogle Scholar
  16. Igwegbe AO, Eleje GU, Ugwueke IF. De novo achondroplasia causing four consecutive unsuccessful pregnancies: a case report. J Med Case Rep. 2012;6:256.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Toriello HV, Meck JM, Professional P, Guidelines C. Statement on guidance for genetic counseling in advanced paternal age. Genet Med. 2008;10:457–60.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Bellus GA, Hefferon TW, Ortiz de Luna RI, Hecht JT, Horton WA, Machado M, Kaitila I, Mclntosh I, Francomano CA. Achondroplasia is defined by recurrent G380R mutations of FGFR3. Am J Hum Genet. 1995;56:368–73.PubMedPubMed CentralGoogle Scholar
  19. Xue Y, Sun A, Mekikian PB, Martin J, Rimoin DL, Lachman RS, Wilcox WR. FGFR3 mutation frequency in 324 cases from the international skeletal dysplasia registry. Mol Genet Genomic Med. 2014;2:497–503.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Matsui Y, Yasui N, Kimura T, Tsumaki N, Kawabata H, Ochi T. Genotype phenotype correlation in achondroplasia and hypochondroplasia. J Bone Joint Surg Br. 1998;80:1052–6.View ArticlePubMedGoogle Scholar
  21. Patil SJ, Banerjee M, Phadke SR, Mittal B. Mutation analysis in Indian children with achondroplasia - utility of molecular diagnosis. Indian J Pediatr. 2009;76:147–9.View ArticlePubMedGoogle Scholar
  22. Sambrook J, Fritsch E, Maniatis T. Molecular cloning: a laboratory manual+ cold Spring Harbor. New York: Cold Spring Harbor Laboratory Press; 1989.Google Scholar
  23. McGuffin LJ, Bryson K, Jones DT. The PSIPRED protein structure prediction server. Bioinformatics. 2000;16:404–5.View ArticlePubMedGoogle Scholar
  24. Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc. 2010;5:725–38.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Zhang Y. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics. 2008;9:40.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Lovell SC, Davis IW, Arendall WB, de Bakker PI, Word JM, Prisant MG, Richardson JS, Richardson DC. Structure validation by Cα geometry: ϕ, ψ and Cβ deviation. Proteins: Structure, Function, and Bioinformatics. 2003;50:437–50.View ArticleGoogle Scholar
  27. Binkowski TA, Naghibzadeh S, Liang J. CASTp: computed atlas of surface topography of proteins. Nucleic Acids Res. 2003;31:3352–5.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Dundas J, Ouyang Z, Tseng J, Binkowski A, Turpaz Y, Liang J. CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Res. 2006;34:W116–8.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Capriotti E, Altman RB, Bromberg Y. Collective judgment predicts disease-associated single nucleotide variants. BMC Genomics. 2013;14(Suppl 3):S2.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Capriotti E, Fariselli P, Casadio R. I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure. Nucleic Acids Res. 2005;33:W306–10.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Bendl J, Stourac J, Salanda O, Pavelka A, Wieben ED, Zendulka J, Brezovsky J, Damborsky J. PredictSNP: robust and accurate consensus classifier for prediction of disease-related mutations. PLoS Comput Biol. 2014;10:e1003440.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Stanescu R, Stanescu V, Maroteaux P. Homozygous achondroplasia: morphologic and biochemical study of cartilage. Am J Med Genet. 1990;37:412–21.View ArticlePubMedGoogle Scholar
  33. Peters K, Ornitz D, Werner S, Williams L. Unique expression pattern of the FGF receptor 3 gene during mouse organogenesis. Dev Biol. 1993;155:423–30.View ArticlePubMedGoogle Scholar
  34. Vajo Z, Francomano CA, Wilkin DJ. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr Rev. 2000;21:23–39.PubMedGoogle Scholar
  35. Li E, Hristova K. Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. Biochemistry. 2006;45:6241–51.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Li E, Hristova K. Receptor tyrosine kinase transmembrane domains: function, dimer structure and dimerization energetics. Cell Adhes Migr. 2010;4:249–54.View ArticleGoogle Scholar
  37. Foldynova-Trantirkova S, Wilcox WR, Krejci P. Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias. Hum Mutat. 2012;33:29–41.View ArticlePubMedGoogle Scholar
  38. Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell. 1996;84:911–21.View ArticlePubMedGoogle Scholar
  39. Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet. 1996;12:390–7.View ArticlePubMedGoogle Scholar
  40. Bocharov EV, Lesovoy DM, Goncharuk SA, Goncharuk MV, Hristova K, Arseniev AS. Structure of FGFR3 transmembrane domain dimer: implications for signaling and human pathologies. Structure. 2013;21:2087–93.View ArticlePubMedGoogle Scholar
  41. Richette P, Bardin T, Stheneur C. Achondroplasia: from genotype to phenotype. Joint Bone Spine. 2008;75:125–30.View ArticlePubMedGoogle Scholar
  42. He L, Horton W, Hristova K. Physical basis behind achondroplasia, the most common form of human dwarfism. J Biol Chem. 2010;285:30103–14.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Volynsky PE, Polyansky AA, Fakhrutdinova GN, Bocharov EV, Efremov RG. Role of dimerization efficiency of transmembrane domains in activation of fibroblast growth factor receptor 3. J Am Chem Soc. 2013;135:8105–8.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement